Latest News for CeCors Stock (OTC:CEOS)

CeCors Inc along with its subsidiaries is engaged in the research and development, production, and commercialization of therapeutic and medicinal entheogenic, adaptogenic, and nootropic ingredients and formulations for its premium functional product lines which are developed by its mycology and botany experts. The company is also engaged in the scientific development of patentable technologies pertaining to the composition, bioavailability, and targeted delivery of entheogen-based therapeutics.

CeCors Inc

Management

Press Releases

VetComm Appoints Accomplished Operations Management Expert as COO to Drive Organizational Success as it Continues its Growth Plan

Earnings

CeCors Reports Record Revenue Following VETCOMM Acquisition

News

VETCOMM Appoints Expert Advisor to Propel Sales and Optimize Claims Processes

Small Cap

Veteran Experts Raise Alarm Bells as Homelessness Rates Increase for the First Time in 12 Years

Contracts

VETCOMM Joins Prestigious Client List, Retains Premier Public Relations Firm BLAZE PR as It Readies for Marketing Launch

On Average, 15 Homeless Veterans Die on the Streets Each Day

VETCOMM Achieves Remarkable Growth: Expands Workforce by 33%, Welcomes Ten New Sales Professionals, Including Two from the Department of Defense's SkillBridge Program

VetComm Urges Action: The Unsettling Impact of Free College on Military Recruitment Threatens National Security

VETCOMM's New Conquer Brand No-Nicotine Pouches Seeks to Carve Out a Share of the Billion-Dollar Market

VETCOMM's Subscription Sales Surge Past $786,000 in 2023; CEOS Prepares for a Record First Quarter in 2024

CEOS

CeCors